About: Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Latest price: $29.39 (-0.12%)
IMVT NASDAQ Immunovant Inc
Immunovant Inc share price
Atividade de preço de IMVT
Último preço
$ 29,390
Variação (24h)
-0,04 USD (0,12%)
Volume
720.59K
Volume (média 4 sem.)
-
Abertura
$ 29,56
Variação do dia
$ 29,33 - $ 30,07
Fechamento anterior
$ 29,42
Último negócio
29 Oct, 4:41 pm GMT+0
Atrasado
29 Oct, 4:41 pm GMT+0
IMVT price performance
Atrasado
29 Oct, 4:41 pm GMT+0
quote.marketSignals